XML 45 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation - Performance-Contingent RSAs and RSUs (Details)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jan. 14, 2016
shares
Jun. 02, 2014
Jun. 30, 2016
USD ($)
shares
Jun. 30, 2015
USD ($)
Jun. 30, 2016
USD ($)
shares
Jun. 30, 2015
USD ($)
Dec. 31, 2011
shares
Stock-based compensation              
Number of shares of Theravance Biopharma issued for every share of Theravance   0.286          
Stock-based compensation expense | $     $ 2,841 $ 1,822 $ 4,704 $ 3,755  
Minimum payout of shares (in shares)         0    
Maximum payout of shares (in shares)         328,688    
Market condition based on relative total shareholder return (TSR) And Service condition based on Performance Measures              
Stock-based compensation              
Timeframe for calculation of TSR         2 years    
RSAs | Vesting on February 20, 2018              
Stock-based compensation              
Portion of options vesting (as a percent)         66.70%    
RSAs | Vesting on February 20, 2019              
Stock-based compensation              
Portion of options vesting (as a percent)         33.30%    
RSAs | Market condition based on relative total shareholder return (TSR) And Service condition based on Performance Measures              
Stock-based compensation              
Granted (in shares) 282,394            
RSUs | Vesting on February 20, 2018              
Stock-based compensation              
Portion of options vesting (as a percent)         66.70%    
RSUs | Vesting on November 20, 2018              
Stock-based compensation              
Portion of options vesting (as a percent)         33.30%    
RSUs | Market condition based on relative total shareholder return (TSR) And Service condition based on Performance Measures              
Stock-based compensation              
Granted (in shares) 46,294            
Special Long-Term Retention and Incentive Cash Awards Program | RSAs | Performance Contingent              
Stock-based compensation              
Shares of common stock approved and authorized for issuance             1,290,000
Timeframe for achievement of performance conditions             6 years
Outstanding (in shares)     63,135   63,135    
Stock-based compensation expense | $         $ 1,200